Movatterモバイル変換

[0]ホーム

Jump to content

Fontolizumab

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Fontolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (frommouse)
Target	interferon gamma
Clinical data
ATC code	none
Identifiers
CAS Number	326859-36-3^N
ChemSpider	none
UNII	6J92H2439Z
KEGG	D04242^Y
Chemical and physical data
Molar mass	ca. 150 kg/mol
^NY (what is this?) (verify)

Fontolizumab (planned trade nameHuZAF) is ahumanized monoclonal antibody^[1] and animmunosuppressive drug for the treatment ofauto-immune diseases likeCrohn's disease.^[2] A phase IIclinical trial investigating the use forrheumatoid arthritis was terminated because the first phase did not meet theendpoint.^[3]

References

[edit]

^Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab,American Medical Association.
^Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. (February 2010)."Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study".Inflammatory Bowel Diseases.16 (2):233–42.doi:10.1002/ibd.21038.PMID 19637334.S2CID 25337474.
^Clinical trial numberNCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" atClinicalTrials.gov

Immunosuppressive drugs /Immunosuppressants (L04)

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitors Azathioprine Mycophenolic acid dihydroorotate dehydrogenase inhibitors Leflunomide Teriflunomide antifolate Methotrexate
Macrolides/ otherIL-2 inhibitors	FKBP/Cyclophilin/Calcineurin Ciclosporin Pimecrolimus Tacrolimus Voclosporin Abetimus Gusperimus
IMiDs	Lenalidomide Pomalidomide Thalidomide PDE4 inhibitor Apremilast
JAK inhibitors	Baricitinib Deucravacitinib Deuruxolitinib Filgotinib Itacitinib Peficitinib Ritlecitinib Tofacitinib Upadacitinib

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra
mTOR	Everolimus Ridaforolimus Sirolimus Temsirolimus Umirolimus Zotarolimus

Extracellular

Antibodies

Monoclonal

Serum target (noncellular)	Complement component 5 Eculizumab TNF Adalimumab Afelimomab Certolizumab pegol Golimumab Infliximab Nerelimomab Interleukin Anakinra Basiliximab Bimekizumab Briakinumab Brodalumab Canakinumab Daclizumab Guselkumab Ixekizumab Netakimab Olokizumab Rilonacept Risankizumab Sarilumab Satralizumab Secukinumab Siltuximab Sirukumab Spesolimab Tildrakizumab Tocilizumab Ustekinumab Interleukin 5 Mepolizumab Immunoglobulin E Omalizumab Interferon Faralimomab IL-6 Elsilimomab IL-12,IL-13, andIL-23 Lebrikizumab Ustekinumab IL-17A Secukinumab
Cellular target	CD3 Muromonab-CD3 Otelixizumab Teplizumab Visilizumab CD4 Clenoliximab Keliximab Zanolimumab CD11a Efalizumab CD18 Erlizumab CD20 Obinutuzumab Ocrelizumab (+hyaluronidase) Pascolizumab Rituximab Ublituximab CD23 Gomiliximab Lumiliximab CD40 Teneliximab Toralizumab CD62L/L-selectin Aselizumab CD80 Galiximab CD147/Basigin Gavilimomab CD154 Frexalimab Ruplizumab BLyS Belimumab CAT Bertilimumab Lerdelimumab Metelimumab Integrin Natalizumab Vedolizumab Interleukin-6 receptor Tocilizumab LFA-1 Odulimomab IL-2 receptor/CD25 Basiliximab Daclizumab Inolimomab T-lymphocyte (Zolimomab aritox)
Unsorted	Alemtuzumab Anifrolumab Atorolimumab Begelomab Bimekizumab Briakinumab Brodalumab Canakinumab Cedelizumab Crovalimab Emapalumab Fontolizumab Guselkumab Inebilizumab Ixekizumab Maslimomab Morolimumab Nipocalimab Ofatumumab Olokizumab Pexelizumab Ravulizumab Reslizumab Risankizumab Rovelizumab Rozanolixizumab Sarilumab Satralizumab Siltuximab Siplizumab Sirukumab Spesolimab Sutimlimab Talizumab Telimomab aritox Teprotumumab Tildrakizumab Vapaliximab Vepalimomab

Polyclonal

-cept (Fusion)

Unsorted

Monoclonal antibodies for theimmune system

Immune system

Human	Immunosuppression:Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Nipocalimab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation:Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other:Bertilimumab Ontamalimab Zanolimumab Combination:Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive:Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab (+berahyaluronidase alfa) Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation:Dostarlimab Other:Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatorylesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Cytokine receptor modulators

Chemokine

Seehere instead.

CSF

Erythropoietin	Agonists:ARA-290 Asialo erythropoietin Carbamylated erythropoietin CNTO-530 Darbepoetin alfa Epoetin alfa Epoetin beta Epoetin delta Epoetin epsilon Epoetin gamma Epoetin kappa Epoetin omega Epoetin theta Epoetin zeta Erythropoietin (EPO) Erythropoietin-Fc Methoxy polyethylene glycol-epoetin beta (CERA/Mircera) Peginesatide Pegol sihematide (EPO-018B)
G-CSF (CSF3)	Agonists:Filgrastim Granulocyte colony-stimulating factor Lenograstim Leridistim Lipegfilgrastim Nartograstim Pegfilgrastim Pegnartograstim
GM-CSF (CSF2)	Agonists:Ecogramostim Granulocyte macrophage colony-stimulating factor Milodistim Molgramostim Regramostim Sargramostim Antibodies:Mavrilimumab Namilumab Otilimab
M-CSF (CSF1)	Agonists:Cilmostim Interleukin-34 Lanimostim Macrophage colony-stimulating factor Mirimostim Kinase inhibitors:Agerafenib
SCF (c-Kit)	Seehere instead.
Thrombopoietin	Agonists:Eltrombopag Pegacaristim Promegapoietin Romiplostim Thrombopoietin (THPO, MGDF)

Interferon

IFNAR (α/β, I)	Agonists:Albinterferon Interferon alpha (interferon alfa, IFN-α) Interferon alfa (IFNA1,IFNA2,IFNA4,IFNA5,IFNA6,IFNA7,IFNA8,IFNA10,IFNA13,IFNA14,IFNA16,IFNA17,IFNA21) Interferon alfa 2a Interferon alfa 2b Interferon alfa n1 Interferon alfacon-1 Interferon alpha-n3 Interferon beta (IFN-β) (IFNB1,IFNB3) Interferon beta 1a Interferon beta 1b Interferon kappa (IFN-ε/κ/τ/ζ, IFNK) Interferon omega (IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies:Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors:Bifarcept
IFNGR (γ, II)	Agonists:Interferon gamma (IFN-γ) Interferon gamma 1b Antibodies:Emapalumab Fontolizumab
IFNLR (λ, III)	See IL-28R (IFNLR)here instead.

Interleukin

Seehere instead.

TGFβ

Seehere instead.

TNF

Seehere instead.

Others

JAK
(inhibitors)

JAK1	Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib
JAK2	Atiprimod AZD-1480 Baricitinib CHZ868 Cucurbitacin I (elatericin B, JSI-124) CYT387 Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994 Pacritinib Peficitinib Ruxolitinib SD-1008 Tofacitinib (tasocitinib)
JAK3	Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P 154 ZM-39923 ZM-449829
TYK2	Deucravacitinib

Others

Additional cytokine receptor modulators:Emfilermin
Lestaurtinib
Midostaurin
Quizartinib
Sorafenib
Sunitinib

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Fontolizumab&oldid=1170236054"

Categories:

Hidden categories:

[8]ページ先頭